How to Buy Igm Biosciences Stock
Igm Biosciences Inc
IGM Biosciences, Inc. , a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases.
Igm Biosciences stock last closed at $9.40, up 22.88% from the previous day, and has decreased 13.6% in one year. It has overperformed other stocks in the Biotechnology industry by 0.09 percentage points. Igm Biosciences stock is currently +146.72% from its 52-week low of $3.81, and -46.89% from its 52-week high of $17.70.
There are currently 58.79M IGMS shares outstanding. The market capitalization of IGMS is $552.59M. In the past 24 hours, 467,477 IGMS shares were traded.
How to Buy Igm Biosciences Stock
Not sure how to invest in Igm Biosciences stock? Here's how.
- Figure out where to buy Igm Biosciences stock: You need to choose an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Igm Biosciences stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Pick your method of payment and add your information.
- Analyze Igm Biosciences stock: The Igm Biosciences ticker symbol is IGMS. Is Igm Biosciences stock a good investment? Should you buy shares of IGMS? How do IGMS's underlying business fundamentals look? Do top analysts think Igm Biosciences is a good buy? Why has IGMS's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if IGMS is a good stock to buy).
- Make your IGMS buy order: Decide if you will purchase IGMS shares at the current market price or use a limit order to buy IGMS stock at a particular price.
- Track your IGMS investment: Create a watchlist to important updates regarding your position in Igm Biosciences stock.
Step 1: Figure out where to buy Igm Biosciences stock
You need a brokerage account to access the NASDAQ market and buy IGMS shares.
Our recommended brokerage: eToro
We believe that eToro is the best brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Financial Services, New York to Tokyo — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro now.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected your brokerage, you need to fill out some personal info so you can invest in IGMS today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open your new brokerage account.
- Submit your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've created your account on the best free stock trading app, your next step is to transfer the money for your investment:
Check out the tutorial below if you need help transferring money into your new investment account.
Step 4: Analyze Igm Biosciences stock
Once you have selected the best place to buy Igm Biosciences stock, it's very important to research their stock prior to buying, so you truly wrap your head around the risk and upside.
Igm Biosciences Numbers
IGMS Overview
WallStreetZen was built to help everyday investors perform more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on IGMS's stock page.
How is IGMS stock valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge IGMS's true value.
Using relative valuations measures:
- IGMS could be undervalued based on its P/B ratio of 2.72x, relative to Biotechnology industry P/B ratio of 5.85x
You can do more valuation research on IGMS's stock here.
IGMS Financials at a glance
Signs that IGMS is financially healthy:
- There are more short-term assets than short-term liabilities on the IGMS balance sheet.
- IGMS has cash burn of 204612000. It has sufficient cash and short-term investments to cover this for at least one year.
- Total IGMS debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the IGMS balance sheet.
Signs that IGMS is not financially healthy:
- IGMS profit margin has gone up by 91.14 percentage points in the past year, but the company is still unprofitable.
- IGMS has a relatively high debt to equity ratio of 1.08.
- IGMS has $338.27M in cash and short term investments. This is not enough to cover its annual cash burn of $204.61M.
Is it a good time to buy Igm Biosciences stock, according to Wall Street analysts?
Out of 6 Equities analysts who track IGMS, the consensus analyst rating on IGMS is a Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Latest IGMS Analyst Forecasts
Stephen Willey, a bottom 5% analyst from Stifel Nicolaus maintains IGMS with a strong buy rating and lowers their IGMS price target from $26.00 to $25.00, on Nov 14, 2023.
You can dive deeper into what analysts are saying on the Igm Biosciences stock forecast page.
IGMS Technical Indicators
IGMS Growth Metrics
Last year, IGMS revenue was $2.13M. During the last 1 years, IGMS's revenue has grown by 99.25% per year. This was faster than the Biotechnology industry average of 28.56%.
Dive into IGMS's earnings and revenue performance here.
Are IGMS executives and large shareholders buying or selling the stock?
Over the last year, insiders at IGMS have bought more shares than they have sold.
Baker Bros Advisors LP, Director of IGMS, was the latest IGMS insider to buy. They bought $860,005.93 worth of IGMS stock on Mar 28, 2024.
Research more about who owns IGMS shares here.
Does IGMS provide a stable income stream?
No, Igm Biosciences doesn't provide an income stream by paying out dividends.
IGMS Social Trading Data
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your IGMS buy order
You have two main options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally the easiest way to buy. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a particular dollar amount limit, place a limit order.
Click the Open button and eToro will execute your order.
If you need more help investing in stocks on eToro, watch the how to video below:
Step 6: Track your IGMS investment
Now that you own some IGMS shares, you'll want to stay up-to-date on your new stock purchase.
Make a watchlist to get notified of the latest news about your IGMS stock.
IGMS Feed
How to Buy Stock in Igm Biosciences
To summarize, here are the 6 steps to buy stock in Igm Biosciences:
- Figure out where to buy Igm Biosciences stock
- Create your brokerage account
- Deposit funds into your investment account
- Analyze Igm Biosciences stock
- Make your IGMS buy order
- Track your IGMS investment
If you are looking for a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest news on your new investment in Igm Biosciences, create your watchlist below.
Other Content You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.